 SAN JOSE, Calif., Aug. 18, 2021 PRNewswire -- Anixa Biosciences, Inc. NASDAQ: ANIX, a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today that the U.S. Patent and Trademark Office has issued the first U.S. patent for its novel ovarian cancer vaccine technology. 